Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sagimet Biosciences Inc. - Series A Common Stock (NQ:SGMT)

2.580 -0.680 (-20.86%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sagimet Biosciences Inc. - Series A Common Stock

< Previous 1 2 Next >
Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat
Call scheduled on Thursday, June 13, 2024 at 9.30 AM PT / 12:30 PM ET 
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
Dr. Scott Friedman to present unmet need in MASH and discuss Sagimet’s topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH 
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
Sagimet announced positive topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH in January 2024 and plans to initiate Phase 3 trial in the second half of 2024 
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock
From Sagimet Biosciences Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.